CClinicalTrials.gg
Status unknownNCT03306459Updated Oct 20, 2017

Psychological Traits, Sexuality and Quality of Life in Patients With Polycystic Ovary Syndrome

An observational study in Polycystic Ovary Syndrome, sponsored by Hospital Clinic of Barcelona. Status unknown at 1 site in Spain. Open to female participants aged 16 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-20.

Sponsored by Hospital Clinic of Barcelona · Observational

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
16 Years to 50 Years
Sex
Female
01

Study summary

A prospective assessment of psychological characteristics, quality of life and sexuality in naïve patients.

Read the detailed description

This project with PCOS patients include an assessment of quality of life and sexuality in naïve patients.

Hypothesizing that PCOS women would show higher rates of psychological alterations, this study is aimed to investigate the association between polycystic ovary syndrome (PCOS) and psychological disturbances, including anger and to analyze whether the biochemical/phenotypical features of PCOS may play a role in the type and severity of psychological disorders.

02

Conditions studied

  • Polycystic Ovary Syndrome

Keywords

  • PCOS
  • Quality of life
  • Sexuality
  • Psychological traits
03

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A)

Inclusion criteria

PCOS patients without gestational desire who met the following criteria

  • Oligomenorrhea (cycles lasting >35 days) or amenorrhea (no periods in 6 months)
  • Hyperandrogenemia/hyperandrogenism Hirsutism Ferriman-Gallwey score > 12 Obvious acne or pronounced alopecia Androgen levels over normal female range

Exclusion criteria

Exclusion Criteria:

  • Prior psychiatric diagnosis
  • Current use of psychiatric medications
  • Difficulties with language comprehension in case of non-nationals.
  • Yatrogenic hirsutism,
  • Other endocrine deseases with hyperandrogenism or that may influence the final results Ovarian or adrenal neoplasia Prolactinoma Cushing's syndrome Congenital adrenal hyperplasia Diabetes mellitus Thromboembolic disease
  • Patients who had received any drug therapy for hirsutism over the last 6 months
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1/PCOS

    The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting \>35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded

    Diagnostic Test: SF-36 (Short Form Health Survey)

  • 2/CONTROL

    The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.

    Diagnostic Test: SF-36 (Short Form Health Survey)

Interventions

  • Diagnostic testSF-36 (Short Form Health Survey)

    Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism). State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health. Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score.

    Also known as: Female Sexual Function Index; Symptom Checklist-90-R; State-Trait-Anger-Expression-Inventory

05

What researchers measure

Primary outcomes

  1. Quality of Life

    results of SF-36

    Time frame: january 9th 2018-january 9th 2019

Secondary outcomes

  1. Sexuality

    Results of FSFI

    Time frame: january 9th 2018-january 9th 2019

  2. Psychological distress

    Results of Symptom Checklist-90-Revision (SCL-90-R)

    Time frame: january 9th 2018-january 9th 2019

  3. Anger and aggressiveness

    results of State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2)

    Time frame: january 9th 2018-january 9th 2019

Other outcomes

  1. Biochemical markers

    Results of blood tests including biochemistry and hormones analysis

    Time frame: january 9th 2018-january 9th 2019

  2. Phenotipical traits

    Record of hirsutism, acne, alopecia, and other hyperandrogenic symptoms

    Time frame: january 9th 2018-january 9th 2019

06

Study locations

1 site
  • Hospital Clínic
    Barcelona, 08036, Spain
    • Camil Castelo-Branco, MD PhD · Contact · ccastelo@clinic.cat · +342275436
    • Juliia Naumova, MD · Principal investigator
07

References and documents

Publications

  • Naumova I, Castelo-Branco C, Casals G. Psychological Issues and Sexual Function in Women with Different Infertility Causes: Focus on Polycystic Ovary Syndrome. Reprod Sci. 2021 Oct;28(10):2830-2838. doi: 10.1007/s43032-021-00546-x. Epub 2021 Mar 24. PubMed 33763818 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03306459
Lead sponsor
Hospital Clinic of Barcelona
Responsible party
Camil Castelo-Branco (Professor, Hospital Clinic of Barcelona) — Principal investigator
First posted
Oct 11, 2017
Start date
Jan 9, 2018 (estimated)
Primary completion
Jan 9, 2019 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Oct 20, 2017

Study contacts

Camil Castelo-Branco, MD PhD
Contact
ccastelo@clinic.cat
1679999037
Camil Castelo-Branco
Contact
Camil Castelo-Branco, MD PhD
study director · Hospital Clínic. University of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion